right now High-Fat Diets Could Pose Danger to Young MS Patients a considerable number of

started out High-Fat Diets Could Pose Danger to Young MS Patients modern-day
 
Photo :High-Fat Diets Could Pose Danger to Young MS Patients

1st Baron Beaverbrook (*this news item will not be available after 01/08/2018) By Mary Elizabeth Dallas Tuesday, October 10, 2017 TUESDAY, Oct. 10, 2017 (HealthDay News) -- A fatty diet may up the risk of relapse in children with multiple sclerosis, according to a new study. But eating a diet rich in vegetables could cut relapse risk in half, the researchers found. The findings may provide early evidence that dietary changes could help some patients with MS manage their condition, said the research team led by Dr. Emmanuelle Waubant. She's a neurologist at the University of California, San Francisco. Multiple sclerosis is a disease of the central nervous system thought to affect more than 2.3 million people worldwide. Symptoms, which often affect movement and vision, can be disabling. Since young people with MS have a higher rate of relapse than adults, Waubant and her colleagues wanted to explore the effects of diet on children with the disease. Food questionnaires were filled out by 219 young patients treated at 11 different MS centers across the United States. All were diagnosed with the relapsing-remitting form of multiple sclerosis or clinically isolated syndrome (CIS) before their 18th birthday. CIS is the first episode of neurological symptoms, usually lasting at least 24 hours. Relapsing-remitting MS means patients have attacks, then are symptom-free for periods of time. The researchers analyzed the patients' dietary data and monitored their health for almost two years on average. During this time, roughly 43 percent suffered a relapse of their disease. The researchers found that every 10 percent increase in calorie intake that came from fat was linked with a 56 percent higher risk of relapse. Moreover, most of this risk increase was tied to consumption of saturated fat, found in many baked goods and beef, cheese and butter. Every 10 percent increase in these calories was associated with a tripling of the risk for relapse, according to the study. But every additional cup of vegetables was linked with a 50 percent reduction in risk for relapse, regardless of how much fat the children ate, the study found. This was true even after the researchers considered other possible contributing factors, including age, weight and medication. It's possible that excess fat intake may be triggering the release of inflammatory chemicals and affecting the composition of bacteria in the gut, the researchers said. Animal fat is also associated with a number of chronic inflammatory conditions, while a vegetable-rich diet has the opposite effect, Waubant's team noted. The findings were published online Oct. 9 in the Journal of Neurology Neurosurgery & Psychiatry . The study doesn't prove a causal relationship, however, and more research is needed to investigate how diet affects MS. "Ultimately, the role of diet in MS is an actively evolving area of research," said Dr. Kathryn Fitzgerald, of Johns Hopkins School of Medicine in Baltimore. She wrote a commentary accompanying the study. SOURCE: BMJ , news release, Oct. 9, 2017 HealthDay Copyright (c) 2017 HealthDay . All rights reserved. News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services. More Health News on Multiple Sclerosis Nutrition Recent Health News smart move


it is important High-Fat Diets Could Pose Danger to Young MS Patients before

Related Posts

running twice daily in patients receiving simeprevir 200 Methadone No clinically important effect on methadone pharmacokinetics 1 Dosage adjustments not needed for either drug 1 Methylphenidate Clinically important interactions not expected 1 Milk thistle ( Silybum marianum ) Possible increased simeprevir concentrations 1 Concomitant use not recommended 1 Naloxone Clinically important interactions not expected 1 Nelfinavir Ritonavir-boosted or unboosted nelfinavir: Possible altered (increased or decreased) simeprevir concentrations 1 Ritonavir-boosted or unboosted nelfinavir: Concomitant use not recommended 1 Nevirapine Possible decreased simeprevir concentrations 1 Concomitant use not recommended 1 200 Proton-pump inhibitors Clinically important interactions not expected 1 Omeprazole: Slightly increased omeprazole concentrations and AUC 1 Omeprazole: Dosage adjustments not needed for either drug 1 Raltegravir No clinically important effect on simeprevir pharmacokinetics 1 Dosage adjustments not needed for either drug 1 Ribavirin In vitro evidence of synergistic activity against HCV; 9 no in vitro evidence of antagonistic anti-HCV effects 1 9 Ribavirin and peginterferon alfa: No effect on simeprevir exposure 1 Rilpivirine No clinically important effect on rilpivirine or simeprevir pharmacokinetics 1 Dosage adjustments not needed for either drug 1 200 Ritonavir Substantially increased simeprevir concentrations and AUC 1 Concomitant use not recommended 1 Saquinavir Ritonavir-boosted or unboosted saquinavir: Possible altered (increased or decreased) simeprevir concentrations 1 Ritonavir-boosted or unboosted saquinavir: Concomitant use not recommended 1 200 Sildenafil Potential increased sildenafil concentrations 1 Sildenafil for pulmonary arterial hypertension (PAH): Dosage adjustment of sildenafil may be needed; 1 consider using lowest initial dosage and titrate as needed with clinical monitoring 1 Sildenafil for erectile dysfunction: Dosage adjustments not needed 1 Sofosbuvir Slightly increased sofosbuvir concentrations and AUC; 1 no clinically important effect on simeprevir pharmacokinetics 1 No in vitro evidence of antagonistic anti-HCV effects between simeprevir and HCV NS5B polymerase inhibitors 1 Dosage adjustments not needed for either drug 1 St. John's wort ( Hypericum perforatum ) Possible decreased simeprevir concentrations; 1 may lead to loss of therapeutic effect of the HCV antiviral 1 Concomitant use not recommended 1 Stavudine Clinically important interactions not expected 1 Tadalafil Possible increased tadalafil concentrations 1 Tadalafil for PAH: Dosage adjustment of tadalafil may be needed; 1 consider using lowest initial dosage and titrate as needed with clinical monitoring 1 Tadalafil for erectile dysfunction: Dosage adjustments not needed 1 Tenofovir Tenofovir disoproxil fumarate (tenofovir DF): No clinically important effect on tenofovir pharmacokinetics; 1 slightly decreased simeprevir concentrations and AUC 1 Tenofovir DF: Dosage adjustments not needed for either drug 1 Tipranavir Ritonavir-boosted tipranavir: Possible altered (increased or decreased) simeprevir concentrations 1 Ritonavir-boosted tipranavir: Concomitant use not recommended 1 200 Vardenafil Possible increased vardenafil concentrations 1 Vardenafil for erectile dysfunction: Dosage adjustments not needed 1 Zidovudine Clinically important interactions not expected 1 Simeprevir Pharmacokinetics Absorption Bioavailability Mean absolute bioavailability: 62% following single 150-mg oral dose under fed conditions. 1 Peak plasma concentrations achieved approximately 4 6 hours after an oral dose. 1 Food Administration after high-fat getting to know


EmoticonEmoticon

:)
:(
=(
^_^
:D
=D
=)D
|o|
@@,
;)
:-bd
:-d
:p
:ng
:lv